---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-284089"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-06-26T13:18:21+00:00"
generated_at: "2026-06-26T13:19:15.378930+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics announces 1-for-20 reverse stock split effective June 29, 2026

## Summary
- Stockholders approved reverse split on June 11, 2026; board set ratio at 1-for-20.
- Certificate of Amendment filed with Delaware Secretary of State on June 26, 2026; effective June 29 at 11:59 pm ET.
- Pre-split shares outstanding: 19,559,257; post-split approx 977,963; CUSIP changes to 22053A305.
- Ticker remains QNCX; options and warrants proportionally adjusted; fractional shares cashed out.

## SEC filing metadata
- accession: 0001193125-26-284089
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-06-26T13:18:21+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526284089/0001193125-26-284089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526284089/d168420d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-284089
- JSON: https://secwatch.observer/filing/0001193125-26-284089.json
- Plain text: https://secwatch.observer/filing/0001193125-26-284089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.